POINT Biopharma (PNT) Investor Presentation June 2023

POINT Biopharma Global Inc. is a radiopharmaceutical company developing next-generation radioligands for oncology with a vertically integrated platform spanning discovery through manufacturing. The company has $519M in cash runway to 2026, operational GMP manufacturing, and late-stage programs including PNT2002 for prostate cancer with up to $1.8B in milestone payments expected from 2025.